A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas(†)

The objective of this phase I study was to determine the maximal tolerated dose (MTD) of erlotinib in patients with recurrent malignant gliomas (MGs) or recurrent meningiomas on enzyme-inducing antiepileptic drugs (EIAEDs). Dose escalation was by a standard 3 × 3 design. The initial starting dose of...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Raizer, Jeffrey J., Abrey, Lauren E., Lassman, Andrew B., Chang, Susan M., Lamborn, Kathleen R., Kuhn, John G., Yung, W.K. Alfred, Gilbert, Mark R., Aldape, Kenneth D., Wen, Patrick Y., Fine, Howard A., Mehta, Minesh, DeAngelis, Lisa M., Lieberman, Frank, Cloughesy, Timothy F., Robins, H. Ian, Dancey, Janet, Prados, Michael D.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2010
Teme:
Clinical Investigations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940559/
https://ncbi.nlm.nih.gov/pubmed/20150371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop017
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki